Clinical trials · New Jersey
Central Nervous System Diseases clinical trials in New Jersey
We’re tracking 15 recruiting central nervous system diseases studies with a site in New Jersey — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New Jersey
- NCT07326566RecruitingPhase 2
Silevertinib and chemo for a type of glioblastoma
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
Hackensack, New JerseyAges 18 years+ - NCT07104032RecruitingPhase 3
Tirabrutinib vs standard therapy for relapsed PCNSL
This study tests a new oral targeted drug called tirabrutinib against a standard treatment combination (rituximab plus temozolomide) for people whose primary central nervous system lymphoma has come back or not responded to prior therapy.
Hackensack, New JerseyAges 18 years+ - NCT07082868RecruitingPhase 1
Study of epcoritamab and ibrutinib for central nervous system lymphoma
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
Basking Ridge, New JerseyAges 18 years+ - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Hackensack, New JerseyAges 18 years+ - NCT07698899RecruitingPhase 1
Study of a new treatment for childhood brain and CNS cancers
This trial tests a radioactive drug (177Lu-DTPA-Omburtamab) given directly into the fluid around the brain for children and teens with certain brain cancers or cancers that have spread to the central nervous system. It aims to see if this treatment is safe and effective for tumors that have come back or not responded to other therapies.
Basking Ridge, New JerseyAges 3–22 - NCT05725499Recruiting
Check if skin stimulation lowers blood pressure drops after spinal injury
This study tests a skin “stimulation” treatment to see if it helps stabilize blood pressure in people with spinal cord injury who get low blood pressure when sitting up. If you often have dizziness, faintness, or low readings after changing positions, this trial may help find safer ways to manage it.
West Orange, New JerseyAges 18–75 - NCT05731986Recruiting
Skin nerve stimulation to raise blood pressure after spinal injury
This study tests whether a device that delivers mild electrical stimulation through the skin can improve low blood pressure after an acute spinal cord injury. It may help reduce episodes of dizziness or faint-feeling caused by blood pressure dropping when you sit up.
West Orange, New JerseyAges 18–75 - NCT07137494RecruitingPhase 1
CAR T-cell therapy for CNS lymphoma
This trial tests a new type of CAR T-cell therapy (MB-CART19.1) for people with central nervous system lymphoma (CNSL) that has come back or not responded to treatment. It aims to see if this therapy can help treat the lymphoma in the brain or spinal fluid.
Basking Ridge, New JerseyAges 18 years+ - NCT07539441RecruitingPhase 1/Phase 2
Mirdametinib for brain and nervous system tumors
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
Middletown, New JerseyAges 18 years+ - NCT04609046RecruitingPhase 1
Lenalidomide and nivolumab added to standard treatment for brain lymphoma
This Phase 1 trial tests adding two cancer medicines—lenalidomide and nivolumab—to the usual treatment for primary CNS diffuse large B-cell lymphoma (a type of lymphoma in the brain/spinal fluid). The goal is to see if the combination is safe and if it works better than the usual approach.
Summit, New JerseyAges 18 years+ - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Hackensack, New JerseyAges 12 months–25 years - NCT04684368RecruitingPhase 2
New treatment study for children and young adults with NGGCT brain tumors
This Phase 2 study tests a new treatment approach for certain brain tumors called NGGCT in children and young adults. It may help improve outcomes by targeting tumors in specific brain locations and using tumor marker tests to guide care.
Hackensack, New JerseyAges 3–29 - NCT07015242RecruitingPhase 2
Liso-cel for newly treated primary CNS lymphoma
This trial tests a new cancer immunotherapy called liso-cel (a CAR T-cell treatment) as a first treatment for people with primary CNS lymphoma who cannot have a stem cell transplant. If you've already received some high-dose methotrexate and your tumor responded, this study may offer a more targeted therapy to try to improve results.
New Brunswick, New JerseyAges 18 years+ - NCT02402244Recruiting
Caring registry study for children and young people with cancer
This study keeps a careful record of children, teens, and young adults with cancer (and some related growths) and may follow them over time. It helps researchers better track outcomes and future contact so care can improve.
Hackensack, New JerseyAges Up to 25 years - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
New Brunswick, New JerseyAges 18 years+
Where these studies are running in New Jersey
Institutions with a site for the recruiting central nervous system diseases studies listed above.
- Rutgers Cancer Institute of New Jersey · 6 studies
- Hackensack University Medical Center · 5 studies
- Memorial Sloan Kettering Basking Ridge · 4 studies
- Memorial Sloan Kettering Bergen · 4 studies
- Memorial Sloan Kettering Monmouth · 4 studies
- Morristown Medical Center · 3 studies
- Newark Beth Israel Medical Center · 3 studies
- Saint Joseph's University Medical Center · 3 studies
What taking part in a central nervous system diseases study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Central Nervous System Diseases trials in other states
Common questions
- Are there central nervous system diseases clinical trials in New Jersey?
- Yes. We're currently tracking 15 recruiting central nervous system diseases studies with a site in New Jersey, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a central nervous system diseases study in New Jersey?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New Jersey to take part?
- Not necessarily. These studies have a site in New Jersey, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a central nervous system diseases trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New central nervous system diseases studies open in New Jersey regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.